Name: AMRX Income Statement - Amneal Pharmaceuticals Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

AMRX - Amneal Pharmaceuticals, Inc.

USD | NASDAQ | Healthcare

AMRX Income Statement - Amneal Pharmaceuticals Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q3 FY 17	Q2 FY 17
Revenues
Revenues	722.5	814.3	784.5	724.5	695.4	730.5	702.5	701.8	659.2	617.0	620.0	599.0	557.5	609.8	545.6	559.4

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenues
Revenues	3,045.9	3,018.8	2,794.0	2,393.6	2,212.3	2,093.7	1,992.5	1,626.4	1,663.0	1,033.7	1,018.2
Cost of Revenue	1,868.3	1,905.5	1,773.5	1,573.0	1,427.6	1,324.7	1,329.6	1,147.2	938.8	507.5	420.8
Gross Profit	1,177.5	1,113.3	1,020.4	820.6	784.7	769.0	663.0	479.2	724.2	526.2	597.5
Operating Expenses
Research & Development	184.5	186.2	190.7	164.0	195.7	201.8	179.9	188.0	194.2	171.4	179.0
Selling General & Administrative	547.4	526.8
Operating Income
Operating Income	435.5	394.1	249.3	204.4	(94.9)	152.7	91.2	(248.7)	(19.7)	245.1	284.9
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-
Tax & Net
Income Tax Expense	0.6	11.3	18.9	8.5	6.7	11.2	(104.4)	383.3	(1.4)	2.0	5.4
Net Income From Continuing Ops	181.3	127.9
Per Share
EPS Basic	0.39	0.23	(0.38)	(0.48)	(0.86)	0.07	0.62	(2.74)	(0.16)	-	-
EPS Diluted	0.37	0.22	(0.38)
Supplementary Data
EBITDA	-	451.4	311.9	270.6	(26.8)	213.4	151.6	(185.4)	44.7	287.1	314.2
EBIT	435.5	394.1	249.3

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	38.4	34.8	63.4	48.0	40.0	54.3	61.1	36.1	39.3	46.1	41.4	37.8	38.7	41.9	50.2	50.7	52.8	51.9	48.9	52.9	48.2	53.5	44.5	45.6	36.4	48.1	38.1	48.0	53.9	57.3	42.3	50.3	44.2	41.3	47.2
Selling General & Administrative	138.9	146.5	137.8	124.3	118.3	128.7	118.7	116.5	112.6	109.0	113.0	105.6	102.1	102.2	100.1	98.8
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of Intangibles	30.0	35.7	39.6	45.8	45.2	50.3	43.3	40.1	39.9	40.7	40.6	40.8	41.1	44.7	44.5	42.0
Other Operating Expenses	6.9	0.0	0.1	0.0	5.1	0.0	1.0	0.0	(0.1)	14.5	(0.1)	(0.0)	1.2	-	1.3	-	-
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Operating Income
Operating Income	141.8	112.0	70.3	111.4	100.3	75.8	88.8	95.5	(10.7)	14.2	75.6	80.1	34.4	36.0	44.4	(198.6)	23.3	11.2	28.5	67.1	45.9	20.2	2.4	10.8	57.8	(23.1)	(112.3)	(18.9)	(94.4)	23.3	74.6	(181.1)	63.6	78.8	44.6

Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	(61.6)	(56.8)	(75.6)	(59.7)	(62.9)	(91.1)	(73.4)	(75.1)	(64.8)	(97.7)	(52.7)	(50.4)	(43.9)	(43.7)	(42.2)	(34.1)
Pre-Tax Income	80.2	55.2	(5.2)	51.7	37.5	(15.3)	15.4	20.4	(75.5)	(83.5)	23.0	29.7	(9.4)	(7.7)	2.2	(232.7)

Tax & Net
Income Tax Expense	2.2	5.7	(23.4)	16.1	12.9	5.4	3.7	3.6	6.2	9.9	(2.1)	(0.0)	0.7	(1.8)	4.6	7.4	(3.5)	4.1	4.0	2.6	0.4	1.5	0.1	2.2	(108.2)	7.8	389.7	(5.7)	(8.4)	5.5	5.1	(12.4)	0.4	(0.7)	1.9
Net Income From Continuing Ops	78.0	49.6	18.1	35.6	24.6	(20.7)	11.8	16.8	(81.7)	(93.3)	25.0	29.7	(10.1)	(5.9)	(2.4)	(240.1)	(6.5)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	78.0	49.6	18.1	35.6	24.6	(20.7)	11.8	16.8	(81.7)	(93.3)	25.0	29.7	(10.1)	(5.9)	(2.4)	(240.1)	(6.5)
Net Income Attributable To Parent	62.3	35.1	2.4	22.4	12.2	(31.1)	(0.2)	6.0	(91.6)	(98.6)	9.7	11.9	(6.9)	(12.0)	(7.6)	(242.1)
Less: Minority Interest	15.7	14.5	15.8	13.2	12.4	10.3	11.9	10.8	10.0	5.3	15.4	17.8	(3.2)	(1.5)	0.3	(119.3)	(4.7)
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	62.3	35.1	2.4	22.4	12.2	(31.1)	(0.2)	6.0	(91.6)	(98.6)	9.7	11.9	(6.9)	(4.3)	(2.7)

Per Share
EPS Basic	0.20	-	0.01	0.07	0.04	-	0.00	0.02	(0.30)	-	0.06	0.08	(0.05)	-	(0.02)	(0.80)	(0.01)	-	(0.03)	0.10	0.05	-	(0.06)	(0.08)	0.78	-	(2.03)	(0.13)	(0.37)	-	0.05	-	-	-	-
EPS Diluted	0.19	-	0.01	0.07	0.04	-	0.00	0.02	(0.30)	-	0.06	0.08	(0.05)	-	(0.02)	(0.80)	(0.01)	-
Shares Basic	316.0	-	314.2	313.7	311.1	-	309.6	309.1	307.3	-	154.2	153.7	152.1	-	151.4	151.0	149.9	-
Shares Diluted	328.9	-	324.8	322.4	324.0	-	309.6	319.0	307.3	-	159.7	154.9	152.1	-	151.4	151.0	149.9	-

Supplementary Data
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91.9	(165.6)	-	89.4	54.3
EBIT	141.8	112.0	70.3	111.4	100.3	75.8	88.8	95.5	(10.7)	14.2	75.6	80.1	34.4	36.0	44.4	(198.6)	23.3	11.2	28.5